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wherein at least one of Ri, R2, R3 and R4 are H or an
acyl having less than about five carbon atoms. More
specifically the preferred purified bioactive compound
is (IR, 1R, 3R, 7S, 7aR)-3-hydroxymethyl-1,2,7-trihy-droxypyrrolizidine.
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NOVEL PYRROLIZIDINE ALKALOID
Investigations relating to the present invention were
supportedin part by research grant HL-17783 from the
National Institutes ofHealth (United States Department
of Health and Human Services).
BACKGROUND OFTHE INVENTION
Castanospermum australe A. Cunn. (Leguminosae),
the Moreton Bay Chestnut or Black Bean, the mono-
typic species of the genus Castanospermum native to
northeastern Australia, has been introduced into the
Indian subcontinent, South Africa and mild climate
areas of North America as an ornamental tree. (1) Cas-
tanospermine (FIG. 4) the major alkaloidal constituent
of the toxic, chestnut-like seeds is a tetrahydroxyin-
dolizidine alkaloid (2) having potent alpha- and beta-
glucosidase inhibitory activity (3,4). The consequent
modification of glycoprotein processing in cells due toinhibition of glucosidase I (5) ) has stimulated consider-
able interest in the biological effects of castanospermine
on a variety of organisms. The alkaloid is an intensely
active feeding deterrent and toxin to certain insects
(6,7), and adversely affects root length growth in a
numberof dicotyledonousplants (8). It has been shown
to alter glycogen metabolism and distribution (9) and to
block the hyperglycemic response to carbohydrates
(10) in rats. In addition, castanospermine inhibits repli-
cation of the human immunodeficiency virus (HIV) (11)
and other retroviruses (12), and reduces tumor growth
in mice (13). Furthermore, the structurally related
trihydroxyindolizidine alkaloid swainsonine (FIG. 7),
the toxic constituent of locoweeds (14) and Australian
Swainsona species (15) is a powerful inhibitor of alpha-
mannosidase and exhibits anti-metastatic immunomodu-
lation towards melanomacells in mice (16). Polyhy-
droxyindolizidine alkaloids and structurally related
analogs may thus represent a class of alkaloids capable
of profoundly influencing diverse biological processes
due to their glycosidase inhibitory activity (17) and
have stimulated efforts to isolate or synthesize addi-
tional compounds in order to delineate structure-
activity relationships.
Among the commontypes of glycoproteins that are
found in eukaryotic organisms, both as cell-associated
proteins and as secreted proteins, are those having N-
linked or asparagine-linked oligosaccharides (18; 19).
The biosynthesis of the oligo-saccharide portion of
these molecules involves a complex sequence of events
beginning with the synthesis of the Glc3Man9(Gl-
cNAc):-pyrophosphoryl-dolicho] intermediate and the
transfer of the carbohydrate portion of this intermediate
to various asparagine residues on the newly-synthesized
polypeptide (20, 21, 22). Following the transfer of this
oligosaccharideto the protein, the newly formed glyco-
protein undergoes a number of modification or “pro-
cessing” reactions whichbegin in the endoplasmicretic-
ulum and continue as the glycoprotein is transported
through the Golgi to its final destination (23, 24, 25, 26).
The initial processing reactions, catalyzed by two
endoplastic reticulum membrane-bound glucosidases,
involve the removal of the three glucose residues. Glu-
cosidase I removes the outermost alpha-1, 2-linked glu-
cose residue, while glucosidase II releases the remaining
two alpha-1, 3-linked glucoses(27, 28, 29, 30, 31). These
trimming reactions give rise to a Mano(GlcNAc)2-
protein which may be acted upon by an endoplasmic
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reticulum-bound alpha-1, 2-mannosidase to give a
Mang(GlcNAc)2-oligosaccharide structure (32, 33).
The Mang.9(GlcNAc)2-protein may be the direct pre-
cursor of the high-mannose glycoproteins, or it may be
further processed, after translocation to the Golgi, to
yield hybrid or complex types of glycoproteins.
In the Golgi, the Mang.o(GlcNAc)2-protein may be
the substrate for mannosidase I which removes the
remaining alpha-1, 2-linked mannose residues, generat-
ing a Mans(GlcNAc)>2-protein (34, 35, 36, 37, 38). This
glycoprotein can then serve as acceptor for GlcNAc
transferase I which catalyzes the addition of a GIcNAc,
from UDP-GlcNAc, to the mannose thatis linked al-
pha-1, 3 to the beta-linked mannose, resulting in the
formation of a GicNAcMans(GlcNAc)2-protein (39, 40,
41). Following this addition a second Golgi mannosi-
dase, mannosidase II, catalyzes the removal of the al-
pha-1, 3 and alpha-1, 6-linked mannoseresidues generat-
ing a GleNAc-Man3(GicNAc)2-oligosaccharide (39,
42). Failure to removethese two terminal mannoseunits
can result in the formation of hybrid types of glycopro-
teins (43, 22). The GlcNAc-Man3(GlcNAc)2-protein
can then be the substrate for a series of glycosyltransfe-
rases forming the complex types of glycoproteins that
contain galactose,sialic acid, fucose, etc. (44, 25).
The study of the biosynthesis of the oligosaccharide
portion of the N-linked glycoproteins has been greatly
facilitated by the use of inhibitors that act at specific
steps in the processing pathway(62, 45). Someof these
. inhibitors which have gained popularity over the past
several years include swainsonine (see FIG.2), a Golgi
mannosidase II inhibitor originally isolated from the
Australian plant Swainsona canescens (15, 46, 47), deox-
ymannojirimycin, a synthetic Golgi mannosidase I in-
hibitor (48, 49, 64), and castanospermine, a glucosidase
I/glucosidaseII inhibitor isolated from the seeds of the
Australian tree Castanospermum australe (2, 5, 50).
SUMMARYOF THE INVENTION
The present invention involves a purified bioactive
compoundof the formula:
 
wherein one or more of Ri, R2, R3 and Ry, are H or
acetyl. Morespecifically the preferred purified bioac-
tive compound is (IR, 2R, 3R, 7S, 7aR)-3-hydroz-
ymethyl-1,2,7-trihnydroxypyrrolizidine.
In an importantaspect, the present invention involves
a method for inhibiting viral or retroviral proliferation
in a host. This method comprises administering a thera-
peutically effective amount of pyrrolizidine alkaloid,
preferably tetrahydroxylated, to said host. The thera-
peutically effective amount should be enough to inhibit
said proliferation without causing host toxicity. The
preferred pyrrolizidine alkaloid for this method is a
purified bioactive compound ofthe formula:
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CH20R+
wherein at least one of Ri, R2, R3 and Rais H or an acyl
having less than about five carbon atoms. Most prefera-
bly the pyrrolizidine alkaloid is (IR, 2R, 3R, 7S, 7aR)-3-
hydroxymethyl-1,2,7-trihydroxypyrrolizidine. One re-
trovirus likely to be so inhibited is HIV-1, the apparent
cause of AIDS.
The present invention also involves a method for
inhibiting glycosidase activity by use of a pyrrolizidine
alkaloid. This method may be practiced in vivo or in
vitro. For an in vitro situation, such inhibition com-
prises incubating glycosidase substrate and glycosidase
in the presenceofa pyrrolizidine alkaloid, preferably of
the formula:
CH20R*
whereinat least one of Ri, Ro, R3 and Ryis H or an acyl
having less than about five carbon atoms. Again, the
most preferred pyrrolizidine alkaloid is (1R, 2R, 3R, 7S,
7aR)-3-hydroxymethy]-1,2,7-trihydroxypyrrolizidine.
A preferred glycosidase particularly sensitive to such
inhibition is alpha glucosidase. A most preferred acyl
groupis acetyl.
BRIEF DESCRIPTION OF THE DRAWINGS
FIG. 1 schematically describes the structure of aus-
traline (IR, 2R, 3R, 7S, 7aR)-3-hydroxymethyl-1,2,7-
trihydroxypyrrolizidine.
FIG. 2 schematically shows the structure of fago-
mine.
FIG. 3 schematically shows the structure of rosmare-
cine.
FIG. 4 schematically showsthe structure of castanos-
permine.
FIG. 5 schematically showsthe structure of 6-epicas-
tanospermine.
FIG. 6 schematically shows the structure of DMDP
(dihydroxymethyl-dihydroxypyrrolizidine).
FIG. 7 schematically showsthe structure of swainso-
nine.
FIG. 8 shows the two-dimensional !H-!3C NMRshift
correlation spectrum ofaustraline [1] in D20.
FIG. 9 shows a perspective view of australine with
crystallographic numbering scheme. The ascending
sizes of shaded circles represent carbon, oxygen and
nitrogen atoms respectively.
FIG.10 showsthe pattern of amyloglucosidase inhi-
bition by australine and castanospermine. Incubations
were as described herein using p-nitrophenyl-alpha-D-
glucoside as substrate. Activity was expressed relative
to untreated enzyme. Australine (AUST), . Cas-
tanospermine (CAST),
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FIG. 11 showsthe effect of substrate concentration
on australine inhibition of amyloglucosidase. Incuba-
tions were as described herein except that various
amounts of p-nitrophenyl-alpha-D-glucoside were
added with inhibitor (0.5 micro g/miaustraline, ;
1 micro g/ml australine, , or without inhibitor
(control, CONT), as indicated. The data were plotted
according to the method of Lineweaver and Burk.
FIG. 12 shows a comparison of the effect of austra-
line and castanospermine onintestinal sucrase activity.
Incubations were as described herein using sucrose as
substrate. Activity is expressed relative to untreated
enzyme. Australine (AUST), . Castanospermine
(CAST),
FIG. 13 shows a comparison of the effect of austra-
line and castanospermine on intestinal maltase activity.
Incubations were as described herein using maititol as
substrate. Activity is expressed relative to untreated
enzyme. Australine (AUST), . Castanospermine
(CAST), .
FIG.14 showsthe effect of australine and castanos-
permine on the activity of the mung bean processing
enzymes, glucosidase I and glucosidase I¥. Conditions
were as described herein. Glucosidase II activity was
determined by monitoring the release of p-nitrophenol
from p-nitropheny!-alpha-D-glucoside (upper panel).
Glucosidase I activity was determined by measuring the
release of [3H] glucose from  glucose-labeled
Gic3MangGlcNAcoligosaccharide (lower panel). Aus-
traline (AUST), . Castanospermine (CAST),
FIG. 15 showsthe effect of australine on the oligo-
saccharide composition of influenza virus glycopro-
teins. Infected MDCKcells were incubated for 2 hours
with 500 micro g/ml australine (lower profiles), and
then labeled with either [3H] mannose (MAN,left) or
[3H] galactose (GAL,right). Control flasks (upper pro-
files) were done in the absence ofalkaloid. After an
incubation of 48 hours, the virus particles were isolated
from treated and untreated cultures by ultracentrifuga-
tion and digested exhaustively with Pronase as de-
scribed herein. The glycopeptides were separated on
columns of Bio-Gel P-4 (1.5 100 cm) (O—0). The en-
tire glycopeptide peak (fractions 32-52 for mannose-
labeled material or fractions 30-48 for glucose-labeled
material) was pooled, digested with Endo H,and re-
chromatographed on the same Bio-Gel co-
jumn(X X). Radioactivity was determined by liquid
scintilation counting. The arrowsindicate the positions
of calibration markers: BD, blue dextran T-2000; S,
stachyose; M, mannose.
FIG. 16 showsa partial characterization of the glu-
cose-labeled oligosaccharide produced in the presence
of australine. The Endo H-released oligosaccharide (see
FIG. 15) from virus grownin the presence of 500 micro
g/ml australine (AUST. OLIGO.) was chromato-
graphed on a 1 200 cm column of Bio-Gel P-4
(200-400 mesh). Radioactivity in various fractions was
determined by liquid scintillation counting. The upper
panel showsthe molecular sizing of the untreated Endo
H-sensitive oligosaccharide while the lower panel
shows the effect of glucosidase I treatment prior to
chromatography. Standard oligosaccharides (arrows)
are Glc3MangGicNAc (12), GleyMangGlcNAc (10),
MangGlcNAc(9), and Man7GicNAc(7). M, mannose.
FIG. 17 shows the methylation analysis of the [3H]
glucose-labeled oligosaccharide australine-grown virus.
The Endo H-released hexose};GlcNAc was isolated
5,021,427
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from the Bio-Gel P-4 column (see FIG. 15) and sub-
jected to complete methylation as described herein.
After acid hydrolysis the methylated sugars were ana-
lyzed by thin-layer chromatography. Radioactive sugar
derivatives were located by scraping plates in 0.5 cm
sections followed by liquid scintillation counting. Stan-
dard sugars are 3,4,5-trimethylglucose, 2,3,4,6=2,4,6-
trimethylglucose, and 2,3,4,6-2,3,4,6-tetramethy!-
glucose.
DESCRIPTION OF THE PREFERRED
EMBODIMENT
During the purification of castanospermine from the
seeds of C. australe, the present inventors noted several
alkaloid fractions, in addition to the castanospermine
fraction, that had inhibitory activity against alpha-
glucosidases. By a combination of ion exchange chro-
matography and preparative centrifugal thin-layer
chromatography, a new alkaloid was isolated and
named “Australine”. The structure of australine (FIG.
1) was established as (1R, 2R, 3R, 7S, 7aR)-3-hydrox-
ymethyl-1,2,7-trihydroxypyrrolizidine. This compound
proved to be a good inhibitor of amyloglucosidase and
the processing glucosidase I. Thisis the first demonstra-
tion that a pyrrolizidine alkaloid may have glycosidase-
inhibitory activity. In addition, Australine inhibited the
processing of glycoproteins in cultured cells. Thus, this
pyrrolizidine structure represents a new repertoire of
chemical structures that can have important inhibitory
activity.
EXAMPLE1
Alkaloid Isolations and Structures
Thin-layer chromatography of the mother liquors
remaining after crystallization of castanospermine (see
FIG.9) from extracts of C. australe seeds had indicatedthe presence of additional alkaloidal constituents.
Separation by preparative centrifugal thin-layer chro-
matography yielded 6-epicastanospermine (FIG.5), an
inhibitor of alpha-glucosidase (67). In one aspect, the
present invention relates to the isolation of fagomine
(FIG. 2), a knownpiperidine alkaloid as well as to the
discovery of a potent, specific alpha-glucosidaseinhibi-
tor, namely australine. The structure of australine was
established by application of one- and two-dimensional
high-field nuclear magnetic resonance (NMR)tech-
niques and mass spectrometry (MS) as a tetrahydrox-
ypyrrolizidine alkaloid, and the stereochemistry of the
substituents was confirmed by single crystal X-ray crys-
tallography. This is the first report of a pyrrolizidine
alkaloid of this type with glycosidase inhibitory proper-
ties and represents a novel structural type within the
class.
Thin-layer chromatographyof the C. australe crystal-
lization mother liquors showed a number of compo-
nents which were less mobile than castanospermine.
One of these constituents gave an intense yellow spot
with acetic anhydride-Ehrlich’s spray reagent and an
orange spot with Dragendorff’s reagent. Separation by
preparative centrifugal thin-layer chromatography
gavea crystalline solid, the melting point, optical rota-
tion, 'H NMR and MSdata of which were consistent
with that of fagomine (1,2,5-trideoxy-1,5-imino-D-
arabino-hexitol), a piperidine alkaloid first isolated from
buckwheat seeds (Fagopyrum esculentum Moench)(68).
The 13C NMR of fagomine was measured and assign-
ments confirmed by a two-dimensional heteronuclear
1H - 13C shift correlation experiment. Although fago-
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6
mine (FIG.2) has not previously been reported to occur
in Leguminosae, the 4-0-(B-D-glucopyranosy])- deriva-
tive has been isolated from seeds of the legume Xantho-
cercis zambesiaca (20). No significant glycosidase inhibi-
tory activity was found when fagomine was tested
against commercially available alpha-and beta-glucosi-
dase, galactosidase and mannosidase, in accord with
previous results (69).
Australine (FIG. 1) was isolated by repeated prepara-
tive centrifugal thin-layer chromatography as a color-
less oil which was crystallized from acetone with some
difficulty as small, dextrorotatory prisms, m.p.
148°-149°. The moleoular formula was determined by
high-resolution mass spectrometry to be CsHisNO4.
The alkaloid. formed a tetraacetate derivative under
mild acetylation conditions indicating the presence of
four primary or secondary hydroxyl groups. However,
on thin layer chromatographythis alkaloid gave a weak
blue-gray spot with acetic anhydride-Ehrlich’s spray
reagent rather than the intense purple spot characteris-
tic of polyhydroxyindolizidine alkaloids. The latter
color is produced by dehydration and rearrangement to
give a pyrrole ring system which undergoes condensa-
tion with the 4-dimethylaminobenzaldehydeat the posi-
tion alpha- to the nitrogen atom (70). The pyrrole ring
generated from australine must therefore bear a substit-
uent blocking the alpha-position. Moreover, the elec-
tron impact mass spectrometry (EIMS) showed no ion
corresponding to the six-membered ring fragment, re-
sulting from cleavageofbondsB to the nitrogen atom in
the pyrrolidine ring moiety (17), typical for castanos-
permine and other indolizidine alkaloids. Instead, the
base peak occurred at m/z 158[M-31]+, indicating loss
of an exocyclic —CH2OHgroup. The fundamentalring
system was thus shownto beof the pyrrolizidine type.
Other major fragments observed in the mass spectrum
were typical for this class of compound,resulting from
cleavageof either of the five-membered rings at bonds
B to the nitrogen atom. The masses of these ions were
such that a single —OH group hadto reside on one ring
while the remaining two —OH groups and the —CH-
20H moiety fully substituted the alternate ring. In all
saturated necine bases previously isolated, such as ros-
marinecine (FIG.3) which bear the —CH2OH groupat
the 1-position, the major mass spectral fragments result
from cleavage ofthe ring system. In contrast, the major
fragmentfrom australine is a consequenceofthe loss of
—CH,0H,,indicating that this substituent must be B to
the nitrogen atom at the 3-position.
Conclusive evidence regarding the presence of a
pyrrolizidine ring system and the position of substitu-
ents was obtained from the 13C and 'H NMRspectra
determined in D2O. Whereas the 13C spectrum ofaus-
traline showed the presence offive methine and three
methylene signals, as in castanospermine (FIG. 4) and
6-epicastanospermine (FIG.5), distinct chemical shift
differences were immediately apparent. Thus, although
two of the methylenesignals (delta-38.1 and deita-54.9)
corresponded closely to those in the five-membered
ring ofthe latter alkaloids, the third signal at delta-65.6
occurred significantly downfield from those observed
for methylene groups at the 5-position of castanosper-
mine (delta-54.3) and 6-epicastanospermine (delta-54.6).
However, its value corresponded well with that ob-
served for the symmetrically disposed ~-CH2OH
groups (delta-63.9) in dihydroxymethyldihydroxypyr-
rolidine (FIG. 6) (DMDP) measured underidentical
5,021,4277
conditions and thus confirmed the occurrence of such a
substituent in australine.
The high-resolution 'H NMRspectrum also demon-
strated notable variations in chemical shifts of the well-
separated groups of signals in comparison to those of
the tetrahydroxyindolizidine alkaloids. In particular,
while castanospermine and its 6-epimer show only a
single signal below delta-4.0, corresponding to the pro-
ton at the hydroxylated 1-position, australine shows two
signals at delta-4.58 and delta-4.41 together with a third
at delta-3.92. In this respect it is comparable to swainso-
nine (FIG. 7) which has —OH groupslocated at the 1-
and 1-positions of the five-membered ring and exhibits
two signals at delta-4.43 and delta-4.33 respectively
with a third at delta-3.88, all of which are due to protons
on hydroxylated positions B to the nitrogen atom.In the
high-field region from delta-1.5-2.5, australine showed
only a two-proton multiplet centered at delta-2.03,
whereas castanospermine has five signals corresponding
to the H-3B, H-5B and bridgehead H-8a protons, which
are essentially trans-diaxial to the nitrogen lone-pair
(71), together with both H-2 protons. However, the
existence of only a single signal at lowerfield (delta-
3.18) and two overlapping signals at delta-2.93 and 3.03
in australine indicated that the latter must be due to the
Hsaipha and H3aipha protons, which are trans-diaxial to
the nitrogen lone pair. Thedifferencesin the 'H spectra,
which are much more apparent than those noted in the
13C spectra, confirm the fundamental distinction be-
tween castanospermine and australine, namely the cis-
fusion of the bicyclic ring system required for a pyr-
rolizidine alkaloid (71), rather than the energetically
favored trans-fusion of the indolizidine alkaloids.
Extensive decoupling experiments established the
connectivity and substitution pattern of australine as
shown in FIG. 1 and yielded the requisite coupling
constants. Of particular significance was irradiation of
the lowest field signal at delta-4.58 which resulted in
collapse of the high-field multiplet at delta-2.03, which
must correspond to H-6-alpha and H-6-beta, and also
the double doublet at delta-3.46, thus identifying the
latter signal as the bridgehead 7a-H. This resonancealso
collapsed upon irradiation of the low-field signal at
delta-4.41, which must be due to H-1, since the only
othersignal affected was the quartet at delta-3.92 (H-2).
Irradiation of the multiplet at delta-3.03 (H-3) influ-
enced not only the H-2 quartet but also the well-separat-
ed-CH2OH proton signals at delta-3.64 and delta3.81.
The non-equivalence of these protons mustbe attributa-
bie either to restricted rotation (71) or to intramolecular
hydrogen-bonding of the hydroxyl group to the nitro-
gen lone-pair. A two-dimensional hetéronuclear !H -
13C shift correlation experiment was used to confirm
assignments of the 13C NMRchemical shifts, the results
of which are shownin FIG.8. The signal for the —CH-
2OH group occurred at delta-65.6 and the bridgehead
C-7a at delta-68.9, as predicted from appropriate models
(14). The four remaining methine carbon atoms, which
are bound either to an oxygen or nitrogen atom, reso-
nated in the narrow range of delta-72.9-77.3.
Determination of the coupling constants from the
above experiments established the identical value of 5
Hz for Jj,7a, Ji,2 and J7,7¢ and a value of 9 Hz for J2,3.
The latter coupling constant is consistent with trans
protons which exist in a near-diaxial situation (theta ~
160°) such as occurin croalbinecine (72) and rosmarine-
cine (FIG.3). In australine therefore the 2-OH and the
—CH,OH groups must havea trans disposition to one
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another. In this event the magnetic non-equivalence of
the —CH2OHprotonsis unlikely to be dueto restricted
rotation. The 5 Hz coupling constants are unfortunately
intermediate in magnitude between those reported for
cis protons and for protons having atrans relationship
in the above examples, and also in swainsonine (FIG.7)
and its di- and tri-acetate derivatives (15). Values ob-
served for protonsin a cis relationship (theta is about
30°) are generally in the range of 3-4 Hz, whereas those
for trans protons are 8-10 Hz. Although the coupling
constants of 5 Hz in australine are somewhat closer to
those expected for cis substitution, chemical evidence
argued against such relationship, at least for the —OH
groupsin the 1- and 1- positions. Thus, treatment of the
alkaloid with 2,2-dimethoxypropane in the presence of
p-toluenesulfonic acid failed to give an acetal deriva-
tive. Moreover, from examination of molecular models,
the stereoisomer in which the —OH groupsat the 1-
and 7-positions bear a cisoid relationship to one another
and are in close proximity, might also have been ex-
pected to yield a six-membered ring acetal derivative.
These results are therefore consistent with a structure
for australine in which the 1-OH groupis trans to those
at the 2- and 7-positions.
In view of the uncertainty of the stereochemical
structure of australine based upon the NMR data, due to
the knownsensitivity of J values to slight variations in
theta in five-membered ring systems, together with the
potential for exo- or endo-flipping in saturated pyr-
rolizidine alkaloids (71), the stereochemistry was ascer-
tained by an alternate method. Crystals sufficiently
large for X-ray crystallographic analysis were obtained,
with somedifficulty, by slow crystallization from ace-
tone and the structure, stereochemistry and absolute
configuration of australine thereby established as (1R,
2R, 3R, 78, 7aR)-3-hydroxymethyl-1,2,7-trihydrox-
ypyrrolizidine. The molecular conformation is illus-
trated as a perspective drawing in FIG. 9. The crystal
structure consists of two crystallographically indepen-
dent molecules within each asymmetric unit. Except for
minor differences in the values of analogous bond
lengths and bondangles, both molecules possess similar
structural features. The two five-membered rings are
symmetrically endo-buckled with C-2 and C-6 being
09.6-alpha above the mean planeofthe other four atoms
of their respective rings. The endo-buckling presumably
reduces non-bonded interaction between H-3-alpha and
H-5-alpha and between H-1 and the —OH groupat the
7-position (71). The molecule is folded along the nitro-
gen-bridgehead carbon bond, resulting in a dihedral
angle between the two ring planes of approximately 54°.
the three hydroxyl groups have a transoid configuration
andthe orientation of the —CH2OHsubstituentis note-
worthy. It assumes a position with the hydroxyl group
directed towards the nitrogen lone pair, enhancing the .
formation of an intramolecular hydrogen bond (0(9) ..
. N(4)=3.1-alpha) and concommitant five-membered
chelate ring, thus accounting for the non-equivalence of
the —CH2OHprotonsin the NMRspectrum.
The molecules in the crystal structure mutually inter-
act with adjacent molecules through an intricate ar-
rangement of intermolecular hydrogen bonds formed
by the nitrogen and oxygen atomsof adjacent unit mol-
ecules. The short intermolecular contacts between oxy-
gen-oxygen and oxygen-nitrogen atoms are within the
range of2.68-2.89-alpha. The unusual feature of the
crystal structure, comprising two crystallographically
independent molecules per assymetric unit, is possibly
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due to the tendency ofthese molecules to form a consid-
erable number of relatively strong hydrogen bonds
between each other, enhancing a more compact and
stable molecular packing in the crystal.
The trihydroxypyrrolizidine alkaloid rosmarinecine
(FIG. 3) had beentested earlier and found to lack gly-
cosidase inhibitory activity. However, australine
proved to be a potent and specific inhibitor of amylo-
glucosidase (an exo-1,4-alpha-glucosidase (Kj=5.2
micro M) whereas castanospermine inhibited both al-
phaglucosidase (K;- 7.9 micro M) and beta-glucosidase.
Nosignificant inhibition of beta-glucosidase, alpha- and
beta-mannosidase or alpha- and beta-galactosidase was
observed.
Australine is therefore not only the first tetrahydrox-
ypyrrolizidine alkaloid to be isolated but also possesses
a unique substitution pattern, bearing the hydroxy-
methyl group at the 3-position rather than the previ-
ously invariant 1-position. In additionit is the sole mem-
ber ofits class to be shownto be a glycosidaseinhibitor.
Previously identified classes of glycosidase inhibitors
have beenlimited to the polyhydroxy-indolizidines(e.g.
castanospermine), - pyrrolidines (e.g. DMDP) and
-piperidines (e.g. nojirimycin). The structure of austra-
line (FIG. 1) is presented in the conventional manner
for all pyrrolizidine alkaloids, namely with the most
highly substituted ring on the right. Its relationship to
castanospermine (FIG.4) can be visualized by inverting
the molecule from right to left.
GENERAL EXPERIMENTAL PROCEDURES.
The alkaloids were monitored for purity by tle on 0.25
mm silica gel plates developed with CHCl3:MeOH:H-
N4OH:H20 (70:26:2:2) and detected by spraying with
acetic anhydride followed by Ehrlich’s reagent (21).
Homogeneity was also checked by gc of the TMS de-
rivatives, prepared by treatment with MSTFAin pyri-
dine, on a Hewlett-Packard 5830 instrument equipped
with a flame-ionization detector, on-column injector,
and a 30-mx0.32-mm id. SE-30 fused silica column.
Lowresolution electron and ammonia chemical ioniza-
tion mass spectra were obtained on a VG Micromass
7070 mass spectrometer; high resolution mass measure-
ments were determined on the same instrument. Optical
rotations were measured in a 1-dm cell on a Perkin-
Elmer 241 automatic polarimeter. Nuclear magnetic
resonance spectra were determined in D2O ona Nicolet
NTC 200FT spectrometer with software package at 200
MHz (!H) and at 50.3 MHz (3C) using 3-(trimethyl-
silyl)-1-propanesulfonic acid (TSP) as an internal stan-
dard. Multiplicities for 13C signals were determined by
application of the carbon attached proton test (CAPT)
sequence. Preparative centrifugal tic was performed on
a Chromatotron Model 7924 (Harrison Research, Palo
Alto, Calif.). Enzyme assay methods have beenprevi-
ously described (67), Melting points are uncorrected.
PLANT MATERIAL. Seeds of C. australe were
collected from the Huntington Botanical Gardens, San
Marino, Calif.
EXTRACTION AND FRACTIONATION. Ma-
ture seeds were ground and extracted with MeOHin a
Soxhlet apparatusandthe alkaloidalfraction purified by
-jon-exchange chromatography on Dowex 50W-H8
(NH4+ form) (2). The eluate was repeatedly subjected
to crystallization from MeOH until no additional cas-
tanospermine, m.p. 217°-219°, could be isolated. Por-
tions of crystallization mother liquors (200 mg.) were
fractionated by preparative centrifugal tlc on a 2 mm.
silica gel plate by sequential elution with
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CHCl3:MeOH:NH,OH:H20 (70:26:2:2) (120 ml.) and
EtOH:NH4OH (98:2) (200 ml.). A total of 70 fractions
(ca. 4.5 ml each) were collected. Fractions showing
similar tle profiles were pooled and concentrated. Re-
sidual castanospermine eluted in fractions 21-32 (70
mg.).
ISOLATION AND CHARACTERIZATION OF
FAGOMINEFIG. 2). Combined fractions 31-44 (22
mg.) gave a discrete, bright yellow spot on tlc
(Rr=0.12) which was slightly less mobile than cas-
tanospermine (RF - 0.14). GC analysis of the TMS de-
rivative gave a single peak with a retention time (R7) of
12.07 mins. Castanospermine has Rr 19.22 mins. The
colorless oil slowly crystallized and was recrystallized
from MeOH-EtOHas white cubes, m.p. 184°-185°,lit.
m.p. for fagomine, 186°-188° (68). The 'H NMR and
mass spectra were completely in accord with data pre-
viously reported for fagomine (68); 3C NMR (50.3
MHz, D20)delta-75.9 (C-3), 75.8 (C-4), 64.2 (C-6), 63.6
(C-5), 45.3 (C-1), 35.3 (C-2); optical rotation {alpha-]24.
lambda (c 0.51, MeOH): +24.4° (589), +25.5°
(578) +28.9° (546), -+48.5 (436), +73.9° (365),lit. [alpha-
]?°delta= 24.7° (c 0.4, H2O) (69). Fagomine showed no
inhibitory activity when tested against a number of
generally available glycosidases, as previously reported(69). :
ISOLATION AND CHARACTERIZATION OF
AUSTRALINE (FIG. 1). Evaporation of combined
fractions 45-65 gave a clear, colorless oil (61 mg.)
which showed a blue-gray spot on tle (Rr=0.08). GC
of the TMSderivative gave a single peak with Rr 17.07
min. Crystallization from Me2CO afforded australine as
colorless prisms, mp 148°-149°; [alpha-]*%jambda(c 2.09,
MeOH):
+
19.3° (589), + 19.9° (578), +22.1°
(546), +32.8° (436), +42.3° (365); 'H NMR (200 MHz
D20)delta-4.58 (1H, q, Jeé-aipha,7 +9 Hz, J7,Jaipha t+ 5 Hz,
H-7), 4.41 (1H, dd, Jj,2=Ji,7-alpha=5 Hz, H-1, 3.92
(1H, dd, Jy2=5 Hz, J2,3=9 Hz, H-2), 3.812 (1H, dd,J3,3=4 Hz, Jgem= — 12 Hz, H-8), 3.64 (1H,dd, J3,3=6.5
Hz, Jgem= —12 Hz, H-8), 3.46 (1H,dd, Jitaipha=57,Jal-
pha=5 Hz, H-7alpha), 3.18 (1H, m, H-5beta), 3.03 (1H,
m, H-3alpha), 2.93 (1H, m, H-Salpha), 2.02 (2H, m,
H-2-alpha, 2beta); 3CNMR (50.3 MHz, D20) delta-
77.3 (C-2), 75.8 (C-7), 74.9 (C-1), 72.9 (C-3), 68.9 (C-7al-
pha), 65.6 (C-8), 54.9 (C-5), 38.1 (C-6; 'H - 13€ 2-D shift
correlation NMR (D20): see FIG. 9; EIMS m/z [M]+
189(5), 159(16), [M-CH2OH] 158(100), 129(10), 128(14),
114(11), 112(43), 98(8), 86(38), 70(22); EIMS (NH3) m/z
[MN]+ 190(100), [MH-H2O[+ 172(6), 158(40); hrms,
mass measurement [M]+ m/z 189.0998 (calcd for
CgH1sNO4, 189.1001).
PREPARATION OF AUSTRALINE TETR-
AACETATE.Australine (10 mg) in dry pyridine (0.3
mi) was treated with Ac2 (0.5 ml) and kept at room
temperature for 20 hours. The clear solution was
poured into H2O (20 ml), the aqueous mixture extracted
with CHCI13 (3 x 10 ml) and the organic layer dried over
anhydrose MgSOg, filtered and evaporated to give a
colorless oil (15 mg); 'H NMR (200 MHz, CDCls) del- -
ta-5.47 (1H, dd), 5.27 (2H, m), 4.17 (1H, dd), 4.04 (1H,
dd), 3.54 (1H, q), 3.22 (1H, m), 3.13 (1H, m), 3.13 (1H,
m), 2.71 (1H, m), 2.15-2.00 (2H, m), 2.13 GH, s,
—OAc), 2.09 (3H, s, —OAc), 2.08 (3H, s, —OAc), 2.04
(3H, s, —OAc); zi3 NMR (50.3 MHz, CDC13) delta-
170.7 (—OCOCHS), 170.5 (—OCOCH3), 170.0 (—O-
COCH3), 169.8 (—OCOCH3), 77.9 (C-6), 73.8 (C-1),
73.4 (C-7), 69.5 (C-5), 66.8 (C-7alpha), 64.4 (C-8), 52.1
(C-3), 33.9 (C-2), 21.1 (—OCOCH3), 20.84 (2x —O-
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COCH3;), 20.76(—OCOCH;); EIMS m/z [M]+
357(0.8), [M - OAc]}+ 314(1.3), 29 (22), [M - CH20Ac]+
28(40), 237(9), 182(21), 178(100), 164(54), 122(50),
43(98); EIMS (NH3), m/z [MH]+ 358(100), 316(3),
297(3), 284(3), 240(4), 236(8), 178(16), 164(6), 136(6),
118(7); hrms, mass measurement [m]+ m/z 357.1431
(calcd. for C16H23NOsx, 357.1423).
It is understood that those skilled in the art of syn-
thetic organic chemistry could readily use numerous
other carboxylic acid anhydrides or chlorides to esterify
one or moreof the hydroxy] groupsof australine. Acyl
functions having less than about five carbon atoms
could be easily synthesized and be likely to have analo-
gousbiological activity.
X-RAY STRUCTURE DETERMINATION. A
single crystal of australine, monoclinic space group,
P2;, a==8.132(2), b=9.337(2), c=21.219(3)alpha, -be-
ta= 106.61(2)° was used. Intensity data was collected on
a Nicolet R3 diffractometer with graphite mono-
chromatized Cu-Kgipho radiation (lambda= 1.5418alpha)
by the theta -2 theta scan technique at room tempera-
ture. The crystal structure was solved by direct meth-
ods. The final least squares structure refinement con-
verged at R=0.050 and R (weighted)=0.063. The abso-
20
lute configuration was determined by comparison of 35
R-values for the two enantiomeric structures.
Australine, a tetrahydroxy pyrrolizidine alkaloid
with a unique substitution pattern, has been isolated
from seeds of Castanospermum australe and shownto be
a potent and specific inhibitor of amyloglucosidase. The
structure was established by a combination of spectro-
scopic and chemical techniques and confirmed by X-ray
crystallography. Australine is the first pyrrolizidine
alkaloid to be identified as a glycosidase inhibitor andis
the third glucosidase inhibitor, together with the in-
dolizidine alkaloids castanospermine and 6-epicastanos-
permine isolated from C. australe. In addition to these
bicyclic alkaloids, the piperidine alkaloid fagomine, a
non-inhibitor, has been isolated from these seeds.
EXAMPLE2
Alkaloid biological activity
Abbreviations used herein include:
Con A, Concanavalin A
Endo H,endo-beta-N-acetylglucosaminidase H
MDCKcells, Madin-Darby canine kidney cells
MES,2-(N-morpholino}ethanesulfonic acid
PBS, phosphate buffered saline
TCA,trichloroacetic acid
TFA,trifluoroacetic acid
Tris, trischydroxymethyl)aminomethane
Materials. {2-3H] Mannose (15 Ci/mmole) and [6-
3H]galactose (15 Ci/mmole) were purchased from
American Radiolabeled Chemicals, Inc. [4,5--H]Leu-
cine (50 Ci/mmole) was obtained from ICN, pronase
was from Calbiochem, and endo-beta-N-acetyl-
glucosaminidase H (Endo H!) was from Miles Scien-
tific. Concanavalin A-Sepharose 4B, maltitol, amylo-
glucosidase (from Aspergillus niger), beta-glucosidase
(from almonds), alpha-galactosidase (from Aspergillus
niger), beta-galactosidase (from bovine liver), alpha-
mannosidase (from jack bean), and all p-nitrophenyl-
glycoside substrates were purchased from Sigma Chem-
ical Company. Beta-Mannosidase was purified from
Aspergillus niger as previously described (51). Glucosi-
dase I and glucosidase II were partially purified from
mung bean seedlings (50). [3H]Glucdse-labeled
Glc3MangGlcNAc-oligosaccharide was isolated from
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influenza virus-infected MDCK cells labeled with [6-
3H]galactose in the presence of castanospermine (52).
Tissue culture materials were obtained from Flow Lab-
oratories. Bio-Gel P-4 and Bio-Gel P-2 were purchased
from Bio-Rad Laboratories, and Sephadex LH-20 was
purchased from Pharmacia Fine Chemicals. Australine
was isolated from Castanospermum australe mother
liquors by ion exchange chromatography and TLC(53).
Castanospermine was isolated from Castanospermum
australe mother liquors by crystallization as reported
elsewhere (2, 54). All additional chemicals were analyti-
cal grade.
Enzyme Assays. (A) glycosidases. The enzymatic
activities of amyloglucosidase, beta-glucosidase, alpha-
and beta-galactosidase, and alpha- and beta-mannosi-
dase were determined colorimetrically by monitoring
the release of p-nitrophenol from the appropriate p-
nitrophenylglycoside substrate (55). All reaction mix-
tures contained 20 micromoles sodium acetate buffer,
pH 5, 2 micromoles of nitrophenyl-glycoside, and en-
zyme in a final volume of 0.4 ml. Incubations were at
37° C. for 15 min, and the reactions were stopped by the
addition of 2.5 ml of 0.4 M glycine, pH 10.4. The p-
nitrophenol liberated in the reaction was measured at
410 nm using a Gilford spectrophotometer. Assays
were done under conditions where the amount of p-
nitrophenol released was linear with both time and
protein concentration. For inhibition studies, australine
(or castanospermine) was preincubated with enzyme
(20 min)prior to the addition of substrate. For competi-
tion analyses, australine and substrate were addedsi-
multaneously.
(B) Sucrase and Maltase. Intestinal sucrase and mal-
tase activities were determined by measuring the forma-
tion of reducing sugar from sucrose and maititol, re-
spectively. The reaction mixture contained 7.5 micro-
moles sodium citrate buffer, pH 6, 9 micromoles of
substrate (sucrose or maltitol), and enzyme, in a final
volumeof0.3 ml. The mixtures were incubatedat 37° C.
for 10 min, and the formation of reducing sugar was
determined by the Nelson method (56). For both en-
zymes, activity was proportional with time, and amount
of protein. As described above for the arylglycosidases,
inhibitors were preincubated with enzyme prior to the
addition of substrate.
(C) Glucosidase I and Glucosidase IH. Glucosidase I
activity was determined by measuring the release of
H]glucose from [3H]glucose-labeled Glc3MangGl-
cNAcas described previously (52). Glucosidase II ac-
tivity was measured by monitoring the release of p-
nitrophenol from p-nitrophenyl-alpha-D-glucoside (55).
Theincubation mixtures for both enzymes contained 50
nM MESbuffer, pH 6.5, 0.1% Triton X-100, enzyme,
and substrate (25,000 cpm of Gle3MangGicNAcfor
glucosidase I; 1.25 micromoles p-nitrophenyl-alpha-D-
glucoside for glucosidase II), in a final volume of 0.25
ml. A typical incubation was for 1 hour at 37° C., and
was linear with both time and protein concentration for
the duration of the assay.
Growth and Labeling of Influenza Virus. The NWS
strain of influenza virus was grown in MDCKcells as
previously described (5, 57). MDCK cells were main-
tained in 75 cm? tissue cultureflasks in modified Eagle’s
medium containing 10% fetal bovine serum. At conflu-
ency, the cells were infected with influenza virus at a
multiplicity of infection of approximately 75PFU. One
hour after infection, australine was added to a final
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concentration of 10-500 micro g/ml. Following an
incubation period of 2 hours to allow the alkaloid to
take effect, [6-3H]galactose or[2-3H}mannose was added
to each culture (both at 25 micro Ci/ml) and the cells
were allowed to incubate for an additional 48 hours to
form mature virus. The presence of mature virus was
determined by hemagglutination. When the titer
reached a maximum,the medium,containing viral parti-
cles and cell debris, was removed and saved, and any
cells still adhered to the flasks were removed with a
rubber policeman and pooled with the medium. The
pooled fraction was subjected to low speed centrifuga-
tion to remove cell debris, and the supernatant was then
centrifuged at 100,000xg for 18 hours to pellet the
virus.
Preparation and Analysis of Glycopeptides. The ma-
ture influenza virus, isolated by ultracentrifugation, was
exhaustively digested with Pronase to obtain a glyco-
peptide fraction for analysis. Briefly, viral pellets were
suspended in 2 ml of 50 mM Tris buffer, pH 7.5, contain-
ing 1 mM CaCl. An equal volume of a 5 mg/ml Pro-
nase solution (in the same buffer) was added, and the
mixtures were incubated at 37° C. for 18 hours under a
toluene atmosphere. The Pronase treatment was re-
peated a second time. The reaction mixture was then
treated with TCA to a final concentration of 5%. After
a 30 min incubation in an ice-water bath, precipitated
protein was removed by centrifugation, and the super-
natantliquid was extracted repeatedly with ethyl ether
to remove any remaining TCA. The neutralized solu-
tion, containing glycopeptides, was then concentrated
to a small volume for analysis by gelfiltration.
Glycopeptides were separated on a 1.5X 100 cm col-
umn of Bio-Gel P-4 (100-200 mesh) equilibrated in 1%
acetic acid. Aliquots of columnfractions were analyzed
for radioactivity to identify the positions of the glyco-
peptide and free sugar(s) peaks. Since this column did
not completely resolve the complex-types of glycopep-
tides from the high-mannosetypes,the entire glycopep-
tide peak was pooled and digested exhaustively with
Endo H.For these incubations the entire glycopeptide
peak was concentrated to dryness and then suspended
in 2 ml of 50 mMcitrate buffer, pH 6. Ten milli units of
Endo H (in the same buffer) was added, and the miz-
tures were incubated at 37° C. for 18 hours under a
toluene atmosphere. At the end ofthis time, a second
addition of Endo H was made (10 m units) and the
incubation was repeated. These digests were then re-
chromatographed on the same Bio-Gel P-4 column and
the Endo H-sensitive peaks.wereidentified by a shift of
the radiolabeled glycopeptide peak to the right (e.,
eluting later from the column).
Characterization of Oligosaccharides. The structure
of the Endo H-sensitive oligosaccharide(s) produced in
the presence of australine was determined by a combi-
nation of chromatographic, enzymatic and chemical
methods. Prior to analysis, each oligosaccharide frac-
tion was subjected to affinity chromatography on Con
A-Sepharose 4B to remove any contaminating complex
type structures. One ml columns of Con A-Sepharose
4B were equilibrated with 50 mM Tris buffer, pH 7.5,
containing 150 mM NaCl, 1 mM CaCh, 1 mM MgCl,
and 1 mM MnCl. The sample was applied to the col-
umn, and the column was washed with 20 ml of the
equilibration buffer. Bound oligosaccharide was eluted
from the column with 100 mM alpha-methylmannoside
in the above buffer, and the free alpha-methylmanno-
side was removed from the oligosaccharide peak by
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desalting on a BioGel P-2 column. Theoligosaccharide
eluting in the void peak of the Bio-Gel P-2 column was
used for structural analysis.
(A) Chromatographic Methods. Endo H-susceptible,
Con A-purified oligosaccharide was chromatographed
on a calibrated 1200 cm column of Bio-Gel P-4
(200-400 mesh), equilibrated in 1% acetic acid. The size
of the oligosaccharide was determinedafter radioactive
counting of the column eluant and comparison to mi-
gration of standard oligosaccharides.
(B) Enzymatic Methods. [?H]Glucose-labeled oligo-
saccharides weretreated with partially purified glucosi-
dase I and glucosidase II to determine their enzymatic
susceptibilities. Digestions were performedas described
for the Enzyme Assays (see above), and were analyzed
by monitoring the release of free glucose and determin-
ing the size of the oligosaccharide product.
(C) Methylation Analysis. [3H]Glucose-labeled oligo-
saccharides producedin the presenceofaustraline were
subjected to exhaustive methylation by a modification
(58) of the method described by Hakomori (59). Lyoph-
ilized oligosaccharide was dissolved in 2 ml of dimeth-
ylsulfoxide undernitrogen, and combined with 1 ml of
dimethylsulfoxide containing 100 mg methylsulfinyl
carbanion. The mixture was sonicated for 5 hours at
40°-50° C., then chilled on ice to 4° C. Two ml of CH3l
were added and the sample was sonicated for 2 hours at
4° C. with the addition of another:2 ml of CHa] after 1
hour. After standing at room temperature overnight,
the mixture was passed through a column of Sephadex
LH-50 equilibrated with 80% methanol (4° C.), in order
to remove dimethylsulfoxide, methylsulfinyl carbanion
and other salts. The column eluates, corresponding to
methylated oligosaccharides, were pooled, concen-
trated to dryness, and hydrolyzed in 2 N TFA at 110°C.
for 4 hours under vacuum. Methylated sugars were then
analyzed by thin-layer chromatography on 0.5 mm
Kiesel Gel 60 F-254 plates (Merck) developed with
benzene:acetone:water:ammonium hydroxide
(50:200:3:1.5). Standard methylated glucose derivatives
prepared from maltose, kojibiose, nigerose, and isomal-
tose were run in parallel lanes. Methylated standards
were visualized by charring the plates after spraying
with 5% ethanolic H2SO4. Radioactive methylated
sugars were detected by scraping the plates into 0.5 cm
sections followed by liquid scintillation counting.
Synthesis of Lipid-linked Saccharides and Protein.
The effect of australine on the formation oflipid-linked
saccharides and on protein synthesis was tested in unin-
fected MDCKcells. Confluent monolayers of MDCK
cells, in 6-well Linbro tissue culture dishes, were treated
for 2 hours with various concentrations of australine
(50-500 micro g/ml) in modified Eagle’s medium con-
taining 10% fetal bovine serum. The cells then were
incubated for 15-120 min with either [2-7H]mannose (20
micro Ci/ml) or [4,5-Hleucine (10 micro Ci/ml) to
label lipid-linked saccharides and cellular proteins, re-
spectively. At the end ofthe labeling period, the me-
dium was removed byaspiration, and the monolayers
were washed 3 times with PB S. One ml of PBS was
added to each well, the cells were dislodged by scrap-
ing, and were then quantitatively transferred to reaction
tubes. Each well was washed with another 1 ml of PBS
and this rinse was also addedto theinitial tube. Radio-
activity incorporatedinto lipid-linked monosaccharides
and oligosaccharides was determined-after extraction
with chloroform:methanol:water (1:1:1) and chloro-
form:methanol:water (10:10:3), respectively, as previ-
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ously described (60). For the incorporation of radiola-
bel into protein, cells were extracted with TCA at a
final concentration of 20% in the presence of 500 micro
g of bovine serum albumin. Following an overnight
incubationat 4° C., precipitated protein was isolated by
centrifugation. The precipitate was washed twice with
5% TCA, and once with absolute methanol, and then
digested with Pronase as described above. Pronase-
released radioactivity was measured by liquid scintilla-
tion counting.
Effect of Australine on Various Glycosidases. Aus-
traline was tested against a number of commercially
available glycosidases to determine inhibitory activity.
Like castanospermine, australine was found to be a
potent inhibitor of amyloglucosidase, an alpha-1 — 4,
alpha-1 — 6 exoglucosidase (FIG.10), with an apparent
Ki of 5.8 micro M. The type of inhibition was competi-
tive in nature (FIG. 11) indicating a structural similarity
to the substrate, similar to that found for castanosper-
mine (4). In contrast to castanospermine, however,
australine was found to be a poor inhibitor of beta-
glucosidase. For example, at levels of castanospermine
which inhibited 50% of the beta-glucosidase activity
(66 micro M), australine inhibited less than 5%.
In addition to alpha- and beta-glucosidase, australine
was also tested against alpha- and beta-mannosidase and
alpha- and beta-galactosidase for inhibitory activity. At
concentrations up to 500 micro M, australine had no
apparent effect on any of these hydrolases.
Effect of Australine on Sucrase and Maltase. The
effects of australine toward other enzymes that are
sensitive to castanospermine, namely intestinal sucrase
and maltase (61), were also measured. Theresults of
these studiesare shown in FIGS. 12 and 13 for sucrase
and maltase, respectively. Although australine did show
significant levels of inhibition within the micromolar
range for both enzymes (Ki of approximately 28 micro
M for sucrase and 35 micro M for malitase), relative to
castanospermine the inhibition was poor (Ki for both
enzymesless than 1 micro M).
Effect of Australine on Processing Glucosidases.
Australine was also tested for inhibitory activity against
partially purified glucosidase I and glucosidase II from
mung bean seedlings. These hydrolases, which are in-
hibited by micromolar amounts of castanospermine(see
FIG. 14), are involved in the initial oligosaccharide
trimming reactions in the endoplasmic reticulum during
N-linked glycoprotein processing. The results shown in
FIG. 14 demonstrate quite clearly that australine selec-
tively inhibits glucosidase I (FIG. 14, lower panel),
having no activity against glucosidase II (FIG. 14,
upper panel) even at concentrations up to 500 micro M.
Althoughthe inhibitory activity toward glucosidase Iis
less potent relative to castanospermine (Ki of approxi-
mately 20 micro M for australine vs. Ki of approxi-
mately 1 micro M for castanospermine), australineis the
first example of a compoundinhibiting glucosidase I
without also inhibiting glucosidase II.
Effect of Australine on Glycoprotein Processing in
Culture. Australine was tested to determine whetherit
would alter normal glycoprotein processing in cell cul-
ture. For these studies, influenza virus-infected MDCK
cells were incubated for 2 hours in the absence or pres-
ence of various concentrations of australine, and then
the cultures were labeled for 48 hours with either [2-
3H]mannose or [6-H]galactose. The mature virus was
isolated by differential centrifugation and digested ex-
haustively with pronase to generate glycopeptides. The
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glycopeptides were then isolated by chromatography
on columnsof Bio-Gel P-4. FIG. 15 showsrepresenta-
tive radioactive profiles of those glycopeptides from
virus raised in the absence (upper panels) or presence
(lower panels) of 500 micro g/ml of australine (0—O).
since these columns did not give good resolution of the
complex from the high-mannose structures, the entire
glycopeptide peak was pooled for each sample, digested
with Endo H, and re-chromatographed on the same
Bio-Gel P-4 (FIG. 15; X—X).
It can be seen from the upperprofiles of FIG. 15 that
the glycopeptides from control virus,labeled with ei-
ther [2H]mannose or PH]galactose, emerged from the
column as a single asymmetrical peak. Exhaustive di-
gestion with Endo H ofthe glucose-labeled glycopep-
tide peak produced no changein the radioactive profile
relative to the undigested material (fractions 30-42),
while treatment of the mannose-labeled glycopeptide
peak (fractions 32-46) with Endo H produced a smaller
second peak (fractions 46-58) containing approximately
18% ofthe total incorporated radioactivity. The bulk of
the radioactivity of the Endo H-treated mannose-
labeled glycopeptide, however, remained in a position
identical to that of the untreated glycopeptide peak, and
like the glucose-labeled material, represents glycopep-
tide with complex oligosaccharide structures. The
smaller second peak most likely represents oligosaccha-
ride of the high-mannose type and is consistent with the
observation that influenza viral hemagglutinin contains
about 20-30% high-mannose oligosaccharide side-
chains (5).
When virus was raised in the presence of 500 micro
g/ml australine, a much different glycopeptide profile
was observedafter Bio-Gel P-4 chromatography (FIG.
15, lower profiles). For both mannose-labeled and glu-
cose-labeled material, there was a shift of the glycopep-
tide peaks, with the bulk of the bound radioactivity
eluting from the Bio-Gel P-4 columnsatlater positions
relative to their controls. Furthermore, when these
glycopeptide peaks were treated with Endo H there
was a massive release of labeled oligosaccharide com-
prising 71% ofthe boundradio-activity in the mannose-
labeled glycopeptide, and 65% of the bound radio-
activity in the glucose-labeled oligosaccharide. These
results indicate that australine altered the normal pro-
cessing of the viral glycoproteins generating a greatly-
increased proportion of high-mannose, Endo H-sensi-
tive oligosaccharides. Moreover, the observation that
the Endo H-released oligosaccharide from the glucose-
labeled glycopeptides contained bound radioactivity
suggested that australine blocked glucose removal,
most likely by an inhibition of glucosidase I.
In addition to the studies shownin FIG.15, australine
was also tested in virus-infected MDCKcell cultures at
several intermediate concentrations, and was found to
affect glycoprotein processing in a dose-dependent
manner. Thus,at a final concentration of 10 micro g/ml
this proportion increased to 55%. Comparable values
for glucose-labeled glycopeptide were 17% and 38%
release of bound oligosaccharide at a final concentra-
tion of 10 micro g/ml and 50 micro g/mlof australine,
respectively.
Australine was tested as an inhibitor of the replication
of the human immunodeficiency virus (HIV-1)in tissue
culture cells. Australine inhibited the growth of the
virus, but this alkaloid was not as effective as an inhibi-
tor as was castanospermine, another alkaloid produced
by this same plant. On the other hand,since australineis
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more specific towards the alpha-glucosidases than is
castanospermine, it should be less toxic that castanos-
permine. It could thus be a better therapeutic agent
even if a high dose is required. In addition, since austra-
line is a pyrrolizidine alkaloid (whereas castanosper-
mine is an indolizidine alkaloid), it may be more easily
chemically synthesized.
Characterization of the Oligosaccharide Produced in
the Presence of Australine. The glucose-labeled, Endo
H-released, oligosaccharide produced in the presence of500 micro g/ml ofaustraline was isolated from the Bio-
Gel P-4 column shown in FIG. 15. After Con A-
Sepharose 4B purification (as described above), the
oligosaccharide was applied to a long calibrated column
of Bio-Gel P-4 to obtain an accurate size determination.
FIG. 16 (upper panel) shows that the majority of the
radioactivity eluted from this column in the position
expected for a hexose;:GlcNAc structure and was
clearly distinct from the hexose)2-GlcNAc and hex-
ose;gGIcNAc standards. This observation was consis-
tent with a Gic3MngGlcNAcoligosaccharide structure.
Further evidence in support of this was obtained by
enzymatic treatment of the Endo H-released oligosac-
charide with glucosidase I (FIG.16, lower panel). Since
this enzyme will only act on structures containing a
terminal alpha-1,2-linked glucose unit, the appearance
of free glucose after incubation is strong proof for the
presence of a Glc3-oligosaccharide structure. There-
sults of FIG. 16 (lower panel) demonstrate quite clearly
that after incubation of the glucose-labeled oligosaccha-
ride with glucosidase I (free of glucosidase II), therewas a release of free glucose coricomitant with a change
in the size of the resulting oligosaccharide to a hex-oseigGIcNAcstructure, consistent with the loss of a
single glucose unit. In addition to these observations,
incubation of the Endo H-released hexose;;GlcNAc
with partially purified glucosidase II (free of glucosi-
dase I) resulted in the release of only small amounts of
radioactive ghicose, suggesting that most of the austra-
line-induced oligosaccharide contained three glucose
residues. ,
Further evidence for a Glc3MangGlcNAc oligosac-
charide structure was obtained by methylation analysis
of the glucose-labeled, Endo H-released oligosaccha-
ride. For these studies, labeled oligosaccharide pro-
duced in the presence of australine was subjected to
exhaustive methylation followed by acid hydrolysis, as
described under Experimental Procedures. Methylated
glucose derivatives were separated by thin-layer chro-
matography and identified by comparison with methyl-
ated glucose standards. The results are shown in FIG.
17. Three major peaks of radioactivity, corresponding
to 3,4,6-trimethylglucose, 2,4,6-trimethylglucose and
2,3,4,6-tetramethylglucose, were observed on the thin
layer plates. Althoughthe relative proportions of these
sugar derivatives did not match the expected 1:1:1 ratio,
the identification of three radiolabeled methylated glu-
cose derivatives does indicate the presence of a Gic3-
oligosaccharide structure. The deviation from the ex-
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pected ratio may be dueto the fact that australine inhibi- 60
tion of glucosidase I is not complete and therefore small
amounts of GlezyMangGlcNAc or GlcyMangGicNAc
could also be present in the oligosaccharide fraction
used for methylation. Thus, in the in vivo- produced
oligosaccharides probably have some inherent hetero-
geneity.
Effect of Australine on the Formation of Lipid-
Linked Saccharides and Protein Synthesis. Since austra-
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line appeared to be an inhibitor of glycoprotein process-
ing, it was important to determine whetherit inhibited
protein synthesis or lipid-linked saccharide formation.
For these studies, uninfected MDCKcells were incu-
bated with various amounts of australine and then la-
beled with either [H]leucine (for protein) or [}H]man-
nose (for lipid-linked saccharide). Radioactivity incor-
porated into protein was determined after TCA precipi-
tation, and radioactivity incorporated into lipid-linked
saccharides was determined after organic extraction as
detailed above.
Tables I and II show the results of australine treat-
ment on protein synthesis and the formation of lipid-
linked saccharides, respectively. It can be seen that
australine hadlittle effect on the overall rate of protein
synthesis (Table I) at concentrations ranging from 50 to
500 micro g/ml, and for times up to 120 min. Similar
results weré observed for the incorporation of (}H]man-
nose into lipid-linked monosaccharides (Table H,left),
although the results are somewhattentative due to the
low degree of radiolabel incorporation. In contrast to
these observations, however, was the finding that the
incorporation of [3H]mannoseinto lipid-linked oligo-
saccharide appeared to be stimulated by australine
(TableII, right), although the magnitude ofthe increase
was small. At present this phenomenonis incompletely
understood, but it may be that australine is inhibiting
competing reactions that utilize mannose, thus increas-
ing the amount of mannoseavailable for in vivo glyco-
sylation.
TABLEI
Effect of Australine on the Incorporation of
H]leucine€ into Protein?
 
Concentration
of australine Radioactivity (cpm) _Incorporated at Time
(micro ug/ml) 30 min 60 min 90 min 120 min
0 8696 15964 24404 35056
50 : 9252 16572 23341 33704
100 8304 1588 25636 32008
250 8064 13604 27776 36140
500 9124 15648 26060 32704
 
Uninfected MDCKcells were grown in 6-well Limbro tissue culture dishes. At
confluency, australine was added to some wells to the final concentration listed
above. After a 2 hours incubation to allow the alkaloid to take effect, [H)leucine
was added to a final concentration of 10 micro Ci/ml, and the incubations were
continued. At the times shown, the medium was removed by aspiration, and the
monolayers were washed three times with PBS. Thecells were released from the
wells by scraping, placed in tubes, and extracted with 20% TCA as described above.
Radioactivity incorporated into total cellular protein was determined after Pronase
digestion by liquid scintillation counting.
TABLEIi
Effect of Australine on the Incorporation
of [3H]mannose into Lipid-linked Saccharides®
 
Concen-
tration Radioactivity (cpm)
of australine Lipid-linked Lipid-linked
(micro monosaccharides oligosaccharides
g/ml) 15min 30min 60min 1Smin 30min 60 min
0 92 136 160 1718 4718 863
50 97 122 229 1672 5021 1077
100 101 151i 244 2336 5335 1104
250 107 115 212 2073 5661 995
5,021,427
19
TABLEII-continued
Effect of Australine on the Incorporation
of [3H]mannose into Lipid-linked Saccharides?
Concen-
tration
 
Radioactivity (cpm)
of australine Lipid-linked Lipid-linked
(micro monosaccharides oligosaccharides
g/ml) 1Smin 30min 6min 15min 30min 60 min
500 96 178 236 2957 6167 1108
 Uninfected MDCK cells were grown in 6-well Limbro tissue culture dishes. At
confluency, australine was added to some wells to the final concentrations listed
above. After a 2 hour incubation to allow the alkaloid to take effect, CPHjmannose
was added to a final concentration of 20 micro Ci/ml, and the incubations were
continued. At the times shown, the medium was removed byaspiration, and the
monolayers were washed three times with PBS. The cells were released from the
wells by scraping, placed in tubes, then sequentially extracted with chloroform:me-
thanol:water (3:1:1)for lipid-linked monosaccharides, and chioroform:methanol:wa-
ter (10:10:3) for lipid-linked oligosaccharides. The total radioactivity incorporated
into the lipid-linked sugars was determined by liquid scintillation counting.
Studies described herein demonstrate that the pyr-
rolizidine alkaloid, australine, is a specific competitive
inhibitor of amyloglucosidase, an alpha-1 — 4, alpha-1
— 6 exoglucosidase (see FIGS. 10 and 11), but does not
inhibit beta-glucosidase or any other alpha- or beta-
glycosidasestested. In addition, australine was a reason-
ably good inhibitor of glucosidase I, but was a very
poor inhibitor of glucosidase II (FIG. 14). Thus, this
alkaloid appearsto be thefirst glucosidase inhibitor that
is active towards glucosidase I without also affecting
glucosidaseII.
Since australine inhibited glucosidase I activity in
vitro, it was tested in cell culture as a potential inhibitor
of glycoprotein processing. For these studies the influ-
enza virus-infected MDCK cell culture system was
employed. The results clearly demonstrated that austra-
line altered the normal glycoprotein processing of viral
glycoproteins (FIG.15), but did not do so by an inhibi-
tion of protein synthesis (Table I) or lipid-linked oligo-
saccharide (or monosaccharide) formation (Table II).
The major oligosaccharide produced in the presence of
australine and released by Endo H appeared to be a
Glc3MangGicNAc structure, based on chromato-
graphic (FIG. 16), enzymatic (FIG. 16) and text), and
chemical (FIG. 17) analyses. Thus, these data were
consistent with the observed inhibition of glucosidase I
by australine, in vitro. However, relative to other pro-
cessing inhibitors, a fairly high concentration of austra-
line was required to produce marked effects on glyco-
protein processing. For example, castanospermine, a
glucosidase I and glucosidase II inhibitor, at a concen-
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tration of 10 micro g/ml, produced the same degreeof.
inhibition (e.g., an increased proportion of Endo H-sus-
ceptible glycopeptides) that was observed for 500 micro
g/ml australine, in vivo (5).
Australine is, however,the first pyrrolizidine alkaloid
that has been shown to havebiological activity and to
be a glycosidase inhibitor. From a structure-activity
point of view, it would appear that the six-membered
ring structure, whichis characteristic of the indolizidine
alkaloids (castanospermine, 6-epicastanospermine and
swainsonine; (62, 18) as well as other related inhibitors
(deoxynojirimycin and deoxymannojirimycin (63, 64)is
not necessary for a compound to be an inhibitor of
glycosidases. Thus, the ring nitrogen andthe configura-
tion of the hydroxyl groups relative to this nitrogen
may be the only factors required for such an inhibitor.
In this regard,it is interesting to point out that several
previous studies showed that the furanose derivatives,
1,4-dideoxy4-imino-D-mannitol and  2,5-dihydrox-
ymethyl-3,4-dihydroxypyrrolidine, were inhibitors of
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mannosidase I and glucosidase I, respectively (65, 66).
Nevertheless, australine with its unique tetrahydrox-
ylated pyrrolizidine structure does add to the growing
list of chemical structures that can have important bio-
logical activity.
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Changes may be madein the chemical substitutions
and functional groups described herein or in the steps or
the sequenceofsteps of the methods described herein
without departing from the concept and scope of the
inventions as defined in the following claims.
Whatis claimed is:
1. A purified bioactive compound having the for-
mula:
 
CH20OR4
wherein at least one of Ri, R2, R3 and R4is H or acyl
having less than about five carbon atoms.
2. The purified bioactive compound of claim 1
wherein Rj, Ro, R3 and Ry are H.
3. The purified bioactive compound of claim 1
wherein R1, R2, R3 and Ry are acetyl.
4. Purified (1R, 2R, 3R, 7S, 7aR)-3-hydroxymethyl-
1,2,7-trinydroxypyrrolizidine.
5. A methodofinterfering with glycoprotein process-
ing in influenza-infected cells, comprising adding an
amountof australine to the cells, the amountbeing suffi-
5,021,42723 24
cient to inhibit glycoprotein processing in influenza- whereinat least one of Ri, R2, R3 and Rg are H oracylhaving less than about five carbon atoms.
infectedcells. . . an 8. The method of claim 5 wherein the bioactive com-6. The method of claim § wherein the australine is poundis australine having the formula:
(IR, 2R, 3R, 7S, 7aR)-3-hydroxymethyl-1,2,7-trihy- 5
droxypyrrolizidine. ,
7. The method of claim 5 wherein the bioactive com-
poundis australine having the formula:
10
 
CH2OR4
wherein each of Ri, Ro, R3 and R4 are acetyl.
15 9. The method of claim 5 wherein the amount of
australine sufficient to inhibit glycoprotein processing
in influenza-infected cells is about 500 pg/ml.
* *£ * & &
 
20
25
30
35
45
50
55
65
